↓ Skip to main content

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)

Overview of attention for article published in Journal of Clinical Oncology, August 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
40 news outlets
blogs
6 blogs
twitter
196 X users
facebook
21 Facebook pages
googleplus
7 Google+ users
video
1 YouTube creator

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
231 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance)
Published in
Journal of Clinical Oncology, August 2015
DOI 10.1200/jco.2015.61.5062
Pubmed ID
Authors

Brendan J Guercio, Kaori Sato, Donna Niedzwiecki, Xing Ye, Leonard B Saltz, Robert J Mayer, Rex B Mowat, Renaud Whittom, Alexander Hantel, Al Benson, Daniel Atienza, Michael Messino, Hedy Kindler, Alan Venook, Frank B Hu, Shuji Ogino, Kana Wu, Walter C Willett, Edward L Giovannucci, Jeffrey A Meyerhardt, Charles S Fuchs

Abstract

Observational studies have demonstrated increased colon cancer recurrence in states of relative hyperinsulinemia, including sedentary lifestyle, obesity, and increased dietary glycemic load. Greater coffee consumption has been associated with decreased risk of type 2 diabetes and increased insulin sensitivity. The effect of coffee on colon cancer recurrence and survival is unknown. During and 6 months after adjuvant chemotherapy, 953 patients with stage III colon cancer prospectively reported dietary intake of caffeinated coffee, decaffeinated coffee, and nonherbal tea, as well as 128 other items. We examined the influence of coffee, nonherbal tea, and caffeine on cancer recurrence and mortality using Cox proportional hazards regression. Patients consuming 4 cups/d or more of total coffee experienced an adjusted hazard ratio (HR) for colon cancer recurrence or mortality of 0.58 (95% CI, 0.34 to 0.99), compared with never drinkers (Ptrend = .002). Patients consuming 4 cups/d or more of caffeinated coffee experienced significantly reduced cancer recurrence or mortality risk compared with abstainers (HR, 0.48; 95% CI, 0.25 to 0.91; Ptrend = .002), and increasing caffeine intake also conferred a significant reduction in cancer recurrence or mortality (HR, 0.66 across extreme quintiles; 95% CI, 0.47 to 0.93; Ptrend = .006). Nonherbal tea and decaffeinated coffee were not associated with patient outcome. The association of total coffee intake with improved outcomes seemed consistent across other predictors of cancer recurrence and mortality. Higher coffee intake may be associated with significantly reduced cancer recurrence and death in patients with stage III colon cancer.

X Demographics

X Demographics

The data shown below were collected from the profiles of 196 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 231 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Sweden 1 <1%
Germany 1 <1%
Korea, Republic of 1 <1%
Unknown 228 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 30 13%
Student > Bachelor 30 13%
Researcher 23 10%
Other 18 8%
Student > Ph. D. Student 18 8%
Other 55 24%
Unknown 57 25%
Readers by discipline Count As %
Medicine and Dentistry 70 30%
Nursing and Health Professions 29 13%
Agricultural and Biological Sciences 14 6%
Biochemistry, Genetics and Molecular Biology 13 6%
Pharmacology, Toxicology and Pharmaceutical Science 7 3%
Other 32 14%
Unknown 66 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 486. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 March 2024.
All research outputs
#54,982
of 25,584,565 outputs
Outputs from Journal of Clinical Oncology
#94
of 22,149 outputs
Outputs of similar age
#491
of 278,161 outputs
Outputs of similar age from Journal of Clinical Oncology
#1
of 286 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,149 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,161 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 286 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.